MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why VALN Stock slipped -0.52% Today — RQD Quant Desk Flash
$5.71 -0.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.69
Valneva SE (VALN) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $541.8M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.69 (-0.28%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.4% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VALN)Realized 20D OHLCV Swing Band: ±7.2%
Deterministic 5-Pillar Attribution (58/100 Composite)
🔍 WHY VALN SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (26% of score)
FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 42.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$5.78-2.9% Next Q
66
Q2 (-2Q)Grade C+$5.61-6.2% Next Q
63
Q3 (-1Q)Grade C$5.26+8.6% Next Q
61
CurrentGrade D+$5.71+0% Hist 90D α
58
Trajectory: B- (66) → D+ (58)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the VALN Bull Thesis Could Fail
Even with a 58/100 (D+) score, VALN faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($6.18) or 200D SMA ($6.82) invalidates the momentum regime and cuts Target Base ($5.71) toward Bear Floor ($4.45).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VALN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VALN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VALN Stock slipped -0.52% Today — RQD Quant Desk Flash
Valneva SE (VALN) slipped -0.52% to $5.71, trading at 13% of its 52-week range ($4.75 – $12.18). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 13% of its 52-week range ($4.75 – $12.18) with RSI-14 at 42.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.2% around $5.71 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $15.2M annual free cash flow.
Live VALN Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VALN)
- ✓Walkthrough of VALN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VALN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +6.13%▲ ASCENDING CHANNEL
2026-10-30O $5.61H $5.71L $5.40C $5.71VOL 7.9K
RES: $7.85SUP: $5.29SMA50: $6.18SMA200: $6.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VALN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VALN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VALN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VALN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VALN)
Health Care Rank #230 of 1016
⚔️ ETRA vs VALN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VALN vs. ETRA, ENTX, SRZN, RGNX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Valneva SE (VALN) ranks #230 by composite RQD confidence (58/100, grade D+) and #435 by equity capitalization ($541.8M). Within this direct 5-issuer industry benchmark cohort, VALN leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VALN
ACTIVE
Valneva SE | D+ | 58/100 | — | — | — | -0.52% | $541.8M | Benchmark Subject |
| ETRA Electra Therapeutics Inc. | D | 48/100 | — | — | — | -3.79% | $542.3M | /etra-vs-valn → |
| ENTX Entera Bio Ltd. | D- | 40/100 | — | 0.0% | -33.6% | +0.65% | $542.6M | /entx-vs-valn → |
| SRZN Surrozen Inc. | E | 27/100 | — | — | -35.0% | -2.93% | $524.4M | /srzn-vs-valn → |
| RGNX REGENXBIO Inc. | D- | 39/100 | — | — | -35.0% | +2.35% | $489.2M | /rgnx-vs-valn → |
2. VALN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTValneva SE (VALN) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $541.8M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
3. VALN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VALN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Valneva SE (NASDAQ: VALN) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $5.71 (-0.52% 1D, market cap $541.8M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VALN ranks #230 in composite RQD confidence.
How does VALN compare to ETRA and ENTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VALN carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ETRA (Electra Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $542.3M) and ENTX (Entera Bio Ltd.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -33.6%, cap $542.6M). Among the 5-stock peer group, VALN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VALN?
For Valneva SE (VALN), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #230 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VALN trading relative to its 50-day, 200-day, and 52-week technical levels?
VALN last traded at $5.71 (-0.52% on volume of 11,519 shares), positioning the stock -7.61% below its 50-day simple moving average ($6.18) and -16.28% below its 200-day simple moving average ($6.82). Across its 52-week range of $4.75 to $12.18, VALN sits at the 12.9% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.2% ($5.30 to $6.12).
VALN Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VALN stock moving today?
Why VALN Stock slipped -0.52% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.